Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

• Published in: Clinical pharmacokinetics Vol. 59; no. 10; pp. 1273 - 1290
• Main Authors: James, Angela Joubert, Smith, Catherine C., Litzow, Mark, Perl, Alexander E., Altman, Jessica K., Shepard, Dale, Kadokura, Takeshi, Souda, Kinya, Patton, Melanie, Lu, Zheng, Liu, Chaofeng, Moy, Selina, Levis, Mark J., Bahceci, Erkut
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.10.2020; Springer Nature B.V
• Subjects: Antibiotics; Antifungal agents; Cytochrome; Drug dosages; Drug interactions; Glycoproteins; Internal Medicine; Leukemia; Medicine; Medicine & Public Health; Mutation; NCT; NCT02014558; NCT02456883; NCT02571816; Original; Original Research Article; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy
• ISSN: 0312-5963; 1179-1926; 1179-1926
• DOI: 10.1007/s40262-020-00888-w

Background and Objective Gilteritinib is a novel, highly selective tyrosine kinase inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 mutation-positive acute myeloid leukemia. This article describes the clinical pharmacokinetic profile of gilteritinib....